Clinical Trial Update: Evaluation of Subcutaneous Desferrioxamine as Treatment for Transfusional Hemochromatosis [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating subcutaneous desferrioxamine for transfusional iron overload has completed, including patients with beta-thalassemia and related condit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Beta-thalassemia
• Hemochromatosis
• Hemoglobinopathy
• Iron Overload
• Thalassemia

Drugs mentioned

• Desferrioxamine (Desferal) (deferoxamine mesylate)

Snippet

Sponsor: National Heart, Lung, and Blood Institute (NHLBI) | Conditions: Anemia (Iron-Loading), Beta-Thalassemia | Phase 2 | Status: COMPLETED